Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
General Internal Medicine
•
Hematology
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
Related Questions
What are the treatment options for relapsed T-ALL in a patient who was nonadherent with AALL and hyper-CVAD regimens?
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
For patients with newly diagnosed AML who are induction chemotherapy eligible, do you dose reduce cytarabine for any mild elevation in AST/ALT?
How would you treat a patient with newly diagnosed low-risk acute promyelocytic leukemia who has a baseline wide QTc interval, such that arsenic trioxide cannot be used?
Would you offer intensive CNS prophylaxis to Ph negative B-ALL patients who have possible mandibular nerve involvement on MRI face?
Do you add venetoclax +/- anti CD-20 mAb to a BTKi in patients with CLL who no longer wish to remain on a BTKi many months after starting the BTKi?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
How has your approach to utilizing MRD-guided therapy in previously untreated CLL changed since the FLAIR trial, particularly in choosing between continuous versus time-limited treatment?
What is your approach to treatment of relapsed, high-risk MDS with TP53 mutation in a patient that is not considered a transplant candidate?
What is the consensus on giving Pemivibart for Pre-Exposure COVID prophylaxis in immunocompromised patients?
